Clinical Trial

Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-20.
Trial Details
NCT Number NCT07433621
Lead Sponsor Children's Hospital Medical Center, Cincinnati
Conditions XIAP Deficiency
Enrollment 12 participants
Start Date 2026-02-26
Primary Completion 2028-11 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-27